Related Party Transactions (Details Narrative) - Pharmsynthez [Member] - USD ($) |
3 Months Ended | |||
|---|---|---|---|---|
Mar. 31, 2023 |
Mar. 31, 2022 |
Dec. 31, 2019 |
Dec. 31, 2022 |
|
| Co Development Agreement [Member] | ||||
| Related Party Transaction [Line Items] | ||||
| Payments to Acquire Notes Receivable | $ 500,000 | |||
| Accrued interest rate | 10.00% | |||
| Interest and Fee Income, Other Loans | $ 0 | $ 9,000 | ||
| Sponsored Research Agreement [Member] | ||||
| Related Party Transaction [Line Items] | ||||
| Prepaid expenses and other current asset | $ 200,000 | $ 400,000 | ||
| X | ||||||||||
- Definition Amount of interest and fee income from loans classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|